4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on the Achondroplasia Pipeline Drugs to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Achondroplasia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 11 ongoing clinical trials involving Achondroplasia
Of the 11 trials,8 trials are in Phase II
Furthermore, 2 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Achondroplasia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Achondroplasia, a Musculoskeletal disorder. Asia-pacific boasts the highest number of ongoing clinical trials involving Achondroplasia. Europe and North America are among some of the other prominent regions involved in Achondroplasia-related drug trials.

BioMarin Pharmaceutical: The leading ongoing Achondroplasia related clinical trial sponsor

BioMarin Pharmaceutical, the United States of America-based pharmaceutical company, is the top sponsor for Achondroplasia-related ongoing clinical trials.

Pfizer, Nagoya University Hospital, Ascendis Pharma, QED Therapeutics, and Sanofi are a few other notable sponsors involving Achondroplasia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Achondroplasia

Vosoritide (voxzogo) and Somatropin (ansomone) are among the key marketeddrugs involving Achondroplasia.     

Vosoritide (voxzogo), an Atrial Natriuretic Peptide Receptor 2 (Atrial Natriuretic Peptide Receptor Type B or Guanylate Cyclase B or NPR2 or EC 4.6.1.2) Agonist drug, is used to treat Achondroplasia and Dwarfism, a Hormonal Disorder. The drug is marketed in the United States of America, Austria, Belgium, Denmark, and the European Union by BioMarin Pharmaceutical. Voxzogo (vosoritide) was first approved in 2021 and is sold in powdered form and administered in solution form through subcutaneous injection.

Somatropin (ansomone), a Growth Hormone Receptor (Somatotropin Receptor or GHR) Agonist drug, is used to treat Achondroplasia, Burns, Growth Hormone Deficiency, Idiopathic Short Stature, Noonan Syndrome, Short Bowel Syndrome, and Shox Deficiency. The drug is sold in China by Anhui Anke Biotechnology (Group). Ansomone(somatropin) was first approved in 2015 and is sold in powdered form and administered in solution form through subcutaneous injection.

Explore the latest trends and actionable insights on the Achondroplasia Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Achondroplasia Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Visit Report Store